OncoNano Medicine to Present Preclinical Data for ON-BOARD™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

OncoNano Medicine, Inc. announced it will be presenting positive preclinical data detailing delivery of interleukin-12 (IL-12) with the ON-BOARD™ platform at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).

ON-BOARD™ is an ultra pH-sensitive tumor delivery platform designed to minimize systemic exposure and toxicity by protecting oncology intervention payloads and releasing them specifically in the acidic tumor microenvironment. The poster presentation will detail encapsulation and delivery of IL-12, a potent pleiotropic cytokine, using ON-BOARD™ in immunocompetent mice.